Статья

Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

M. Yu. NadinskaiaDepartment of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaМ. V. MaevskayaVasilenko Clinic of Internal Diseases Propedeutics, Gastroenterology and Hepatology, University Clinical Hospital №2, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia. [email protected]В. Т. ИвашкинDepartment of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaKh. B. KodzoevaDepartment of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, RussiaИ. Ю. ПироговаLLC MC "Lotus", Center for Gastroenterology and Hepatology, Chelyabinsk 454092, RussiaEvgeny ChesnokovDepartment of Hospital Therapy with the Course of Endocrinology and Clinical Pharmacology, Tyumen State Medical University, Tyumen 625003, RussiaAlexander NersesovDepartment of Gastroenterology, S. Asfendiyarov Kazakh National Medical University, Almaty 050000, KazakhstanJamilya KaibullayevaDepartment of Gastroenterology, S. Asfendiyarov Kazakh National Medical University, Almaty 050000, KazakhstanAkzhan KonysbekovaFunctional and Ultrasound Diagnostics, Scientific and Research Institute of Cardiology and Internal Diseases, Almaty 050000, KazakhstanA. RaissovaDepartment of Internal Diseases, Scientific and Research Institute of Cardiology and Internal Diseases, Almaty 050000, KazakhstanF. I. KhamrabaevaFaculty of Therapy, Tashkent Institute of Advanced Medical Studies, Tashkent 100007, UzbekistanЕ. Б. ЗуеваDepartment of Therapy № 1 with Training General Practitioners, Tashkent Medical Academy, Tashkent 100109, Uzbekistan

World Journal of Gastroenterologyjournal2021en

ABI

Аннотация

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties. AIM: To evaluate the effects of 6 mo of UDCA treatment on hepatic function tests, lipid profile, hepatic steatosis and fibrosis, atherogenesis, and ASCVD risk in men and women with NAFLD, as well as to assess the impact of > 5% weight reduction on these parameters. METHODS: -test, Fisher's exact test, and Pearson's chi-squared test were used. RESULTS: < 0.001). The changes in ALT, aspartate transaminase, glutamyltransferase, total cholesterol, and low-density lipoprotein levels were similar between the subgroups. CONCLUSION: UDCA normalizes liver enzymes greatly within the first 3 mo of treatment, improves lipid profile and hepatic steatosis independent of weight loss, and has a positive effect on CIMT in the total sample and 10-year ASCVD risk in women after 6 mo of treatment.

Перевод пока недоступен

Темы

Liver Disease Diagnosis and Treatment Drug-Induced Hepatotoxicity and Protection Liver Diseases and Immunity

Идентификаторы

DOI: 10.3748/wjg.v27.i10.959

Цитирования и источники

Цитирований: 0Использованных источников: 70

Показатели — AkademScholar